X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs TEVA PHARMA (Israel) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   TEVA PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
TEVA PHARMA
Dec-13
SANOFI INDIA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs4,9452,979-   
Low Rs3,9012,588-   
Sales per share (Unadj.) Rs1,081.81,709.7-  
Earnings per share (Unadj.) Rs141.6106.8-  
Cash flow per share (Unadj.) Rs185.9245.0-  
Dividends per share (Unadj.) Rs33.0093.49-  
Dividend yield (eoy) %0.73.4 22.2%  
Book value per share (Unadj.) Rs868.81,899.1-  
Shares outstanding (eoy) m23.03848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.11.6 251.1%   
Avg P/E ratio x31.226.1 119.9%  
P/CF ratio (eoy) x23.811.4 209.4%  
Price / Book Value ratio x5.11.5 347.4%  
Dividend payout %23.387.5 26.6%   
Avg Mkt Cap Rs m101,8622,360,349 4.3%   
No. of employees `0003.244.9 7.2%   
Total wages/salary Rs m3,6850-   
Avg. sales/employee Rs Th7,691.932,257.4 23.8%   
Avg. wages/employee Rs Th1,137.70-   
Avg. net profit/employee Rs Th1,006.52,015.1 49.9%   
INCOME DATA
Net Sales Rs m24,9141,449,810 1.7%  
Other income Rs m8070-   
Total revenues Rs m25,7211,449,810 1.8%   
Gross profit Rs m5,372397,031 1.4%  
Depreciation Rs m1,022117,190 0.9%   
Interest Rs m1128,477 0.0%   
Profit before tax Rs m5,146251,365 2.0%   
Minority Interest Rs m01,142 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-165,007 0.0%   
Tax Rs m1,886-3,069 -61.5%   
Profit after tax Rs m3,26090,569 3.6%  
Gross profit margin %21.627.4 78.7%  
Effective tax rate %36.6-1.2 -3,001.9%   
Net profit margin %13.16.2 209.5%  
BALANCE SHEET DATA
Current assets Rs m14,432979,196 1.5%   
Current liabilities Rs m6,010853,942 0.7%   
Net working cap to sales %33.88.6 391.3%  
Current ratio x2.41.1 209.4%  
Inventory Days Days6191 67.1%  
Debtors Days Days2896 29.7%  
Net fixed assets Rs m7,991473,540 1.7%   
Share capital Rs m2303,569 6.5%   
"Free" reserves Rs m19,7780-   
Net worth Rs m20,0081,610,464 1.2%   
Long term debt Rs m0741,320 0.0%   
Total assets Rs m27,7703,313,281 0.8%  
Interest coverage x468.89.8 4,770.7%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.90.4 205.0%   
Return on assets %11.83.6 327.8%  
Return on equity %16.35.6 289.7%  
Return on capital %25.84.9 522.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m1,0490-   
CASH FLOW
From Operations Rs m4,351231,025 1.9%  
From Investments Rs m-787-81,861 1.0%  
From Financial Activity Rs m-1,884-277,130 0.7%  
Net Cashflow Rs m1,680-127,966 -1.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 71.37 Rs / USD

Compare SANOFI INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare SANOFI INDIA With: AJANTA PHARMA  SUVEN LIFE  PANACEA BIOTECH  VENUS REMEDIES  AUROBINDO PHARMA  



Today's Market

Where Will the Two-Faced Market Go from Here?(Podcast)

The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.

Related Views On News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

Feb 4, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)

Feb 5, 2019

A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Do You Have the Stomach to Survive a Small Cap Crash?(Profit Hunter)

Feb 5, 2019

While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 15, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS